Equities research analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to report ($0.79) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Coherus Biosciences’ earnings. The highest EPS estimate is ($0.77) and the lowest is ($0.82). Coherus Biosciences posted earnings of ($1.09) per share during the same quarter last year, which would indicate a positive year over year growth rate of 27.5%. The firm is scheduled to issue its next earnings results on Monday, November 5th.
On average, analysts expect that Coherus Biosciences will report full year earnings of ($3.03) per share for the current year, with EPS estimates ranging from ($3.07) to ($3.00). For the next financial year, analysts anticipate that the business will report earnings of ($1.22) per share, with EPS estimates ranging from ($2.04) to $0.15. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Coherus Biosciences.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.04).
A number of equities research analysts have recently commented on CHRS shares. BidaskClub cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, June 16th. Zacks Investment Research upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a report on Tuesday, June 19th. ValuEngine upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, June 21st. Finally, HC Wainwright started coverage on shares of Coherus Biosciences in a research report on Tuesday, August 28th. They set a “buy” rating and a $28.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $23.75.
In related news, CFO Jean-Frederic Viret sold 9,291 shares of the stock in a transaction that occurred on Monday, July 23rd. The shares were sold at an average price of $18.56, for a total transaction of $172,440.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Barbara K. Finck sold 1,760 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $19.02, for a total transaction of $33,475.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,811 shares of company stock worth $751,117. 19.57% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new position in Coherus Biosciences during the first quarter valued at approximately $115,000. Tower Research Capital LLC TRC bought a new position in Coherus Biosciences during the second quarter valued at approximately $118,000. Hartwell J M Limited Partnership bought a new position in Coherus Biosciences during the second quarter valued at approximately $140,000. Dynamic Technology Lab Private Ltd bought a new position in Coherus Biosciences during the second quarter valued at approximately $193,000. Finally, BlueMountain Capital Management LLC bought a new position in Coherus Biosciences in the second quarter worth approximately $214,000. Institutional investors own 91.31% of the company’s stock.
NASDAQ:CHRS opened at $13.33 on Wednesday. Coherus Biosciences has a 52 week low of $8.05 and a 52 week high of $20.66. The company has a debt-to-equity ratio of 1.66, a quick ratio of 7.79 and a current ratio of 7.79. The company has a market cap of $1.12 billion, a PE ratio of -2.98 and a beta of 3.67.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Recommended Story: Earnings Per Share (EPS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.